This page uses content from Wikipedia and is licensed under CC BY-SA.


Indacaterol structure.svg
Indacaterol ball-and-stick model.png
Clinical data
Trade namesOnbrez, Arcapta
AHFS/Drugs.comInternational Drug Names
License data
  • US: C (Risk not ruled out)
Routes of
ATC code
Legal status
Legal status
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.218.577 Edit this at Wikidata
Chemical and physical data
Molar mass392.499 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist[1] developed by Novartis. It needs to be taken only once a day,[2] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

Medical uses

A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.[3]


It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009,[4] and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011.[5] In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals.[6]


  1. ^ Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567.
  2. ^ Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (May 2007). "Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma". Eur. Respir. J. 29 (5): 871–8. doi:10.1183/09031936.00060006. PMID 17251236.
  3. ^ Geake, James B (2015). "Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease". Reviews. 1: CD010139. doi:10.1002/14651858.CD010139.pub2. PMC 6464646. PMID 25575340.
  4. ^ European Public Assessment Report for Onbrez Breezhaler Archived 2010-01-16 at the Wayback Machine
  5. ^ "FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease" (Press release). U.S. Food and Drug Administration. 2011-07-01. Retrieved 2011-07-02.[1]
  6. ^ Faulkner, Sarah (22 December 2016). "Sunovion, Novartis ink licensing deal for inhaled COPD drugs". Drug Delivery Business.